Nanotechnology in Diabetes Management

Nanotechnology is a scientific and technological combination, integrating various fields, such as physics [1], chemistry [2], biotechnology and engineering [3]. It is considered as the manipulation of matter with at least one dimension sized from 1 to 100 nanometers [4]. The interesting potential of nanotechnology, due to the special properties of nanomaterials, leads to a great number of applications, which are developed in order to improve the quality of life [5]. Nanomedicine is a specialized branch of medicine that applies the fundamentals of nanotechnology to the prevention and/or the treatment of various diseases [6]. Thus, nanomedicine involves the utilization of nanostructured materials for diagnosis, delivery, detection or actuation purposes in a living organism [7]. There are numerous companies specializing in the fabrication of new forms of nanosized matter, with anticipated applications that include medical therapeutics and diagnostics, energy production, molecular computing and structural materials [4,8]. Nanotechnology can enhance drug delivery to those areas which were unfavorable for macromolecules to approach [9]. Furthermore, it offers new implantable sensing technologies, providing accurate medical information [10]. Cancer and cardiovascular diseases diagnosis and treatment, dental applications and development of bone implants are among the most famous applications of nanomedicine [11-16]. Diabetes is considered to be among the major afflictions of modern western society. Recent studies demonstrated that around approximately 9.3 percent of the global adult population suffered from diabetes in 2019 [17]. According to mathematical models, based on clinical data, by the year 2045, this percentage is expected to rise to almost 11 percent [17,18]. Diabetes is typically characterized by increased thirst, excessive weight loss or excessive desire to eat, increased urge for urination and thus resulting in abnormal increase in blood glucose level [19,20]. It is classified as Type 1, Type 2 or gestational diabetes mellitus, depending on the reason for high blood sugar [19-21]. In type 1-diabetes, the body cannot produce insulin due to loss of β-cells, as a result of T-cell mediated autoimmune attack [22]. The common approach of this condition is a prescribed insulin replacement therapy, including injections of long-acting insulin at mealtimes [23]. An insulin-resistance combined with insulin deficiency Crimson Publishers Wings to the Research Review Article